This article is more than 5 years old. Information may no longer be current.
VIDEO: Merge of Immunotherapy, Genomics Lead to Personalized Treatment
Click Here to Manage Email Alerts
CHICAGO — Candace Johnson, PhD, president and CEO of Roswell Park Cancer Institute, discusses how research in immunotherapy and genomics can lead to tailored personalized treatments at the ASCO Annual Meeting.
She highlights sessions that focused on how physicians can capitalize on genomic information so patients can receive proper immunotherapies, as well as how to find biomarkers to help predict which patients may respond well to CAR T-cell therapy.
“Immunotherapy is everywhere, and if you would have come to this meeting 10 years ago, you wouldn’t have seen that,” Johnson said. “Immunotherapy and genomics are coming together [to evaluate] how we can better design these immunotherapeutic approaches based on a personalized medicine advantage.”